ArticleTranslational cancer research2025
TFP12 as a key regulator of sentinel lymph node metastasis in breast cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer remains one of the most prevalent malignancies worldwide, with sentinel lymph nodes (SLNs) serving as critical gateways for early metastasis. While SLN status is routinely used for clinical staging, the molecular features of SLN-associated genes and their prognostic significance are not fully understood. This study elucidates the functional roles of SLN-associated genes in breast carcinogenesis, establishing a molecular subtyping framework with prognostic significance through integrated multi-omics analysis. Methods: Differential expression analysis utilizing high-throughput sequencing was conducted to identify SLN-associated genes. Additionally, Molecular subtyping was performed through ConsensusClusterPlus, followed by implementation of a least absolute shrinkage and selection operator (LASSO) regression-based predictive modeling framework to establish the optimal prognostic stratification system. Finally, functional annotation analyses integrated multi-platform databases systematically decoded the biological networks underlying the prognostic model. Functional validation through Transwell migration and scratch wound healing assays confirmed TFP12's impact in breast cancer. Results: This study revealed 218 SLN-associated genes, with functional enrichment predominantly involving TNF signaling pathway regulation. We discovered that EPCAM, TIMP1, and CD19 are potent regulators of the expression of these 14 genes. ConsensusClusterPlus application stratified breast cancer samples into two distinct molecular subtypes. LASSO regression constructed a prognostic model showing significant associations with immune cell infiltration dynamics and therapeutic resistance mechanisms. In the subsequent basic experimental verification, our analysis revealed that TFP12 suppresses breast cancer invasion and migration, with significant correlations to metastasis-related genes Conclusions: This investigation reveals the pivotal role of SLN-associated genes, thereby elucidating the intricate mechanisms underlying the progression of breast cancer. The established prognostic framework provides mechanistic perspectives for developing actionable therapeutic targets in translational oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.